吉林長龍藥業(08049.HK)一季度純利增55.85%至5238.8萬元
格隆匯4月19日丨吉林長龍藥業(08049.HK)公佈,截至2023年3月31日止三個月,公司營業額為人民幣1.43億元,同比減少26.28%;公司股東應占期內盈利為人民幣5238.8萬元,同比增長55.85%;基本每股盈利為人民幣9.35仙。
截至2023年3月31日止三個月之邊際毛利率約70.7%,較截至2022年3月31日止期間的83.7%有13%之減少。董事會相信,生產及材料成本並無發生重大波動。
2023年分銷及銷售成本佔營業額之比率為44.2%,較去年同期之46.8%減少2.6%。行政開支由截至2022年3月31日止三個月人民幣3715.3萬元減少至2023年同期人民幣1638.7萬元。分銷及銷售成本及行政開支減少並未超出本集團之月度預算,並符合集團於2023年策略規劃內之預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.